abstract |
the present invention relates to DNA agents, for example, double-stranded DNA (DNA) agents, which target the hmgb1 gene. the invention also relates to methods of using such renal agents to inhibit the expression of an hmgb1 gene and methods of preventing and treating a hmgb1-associated disorder, for example, metabolic disorder or non-alcoholic fatty liver disease, for example , non-alcoholic steatohepatitis (nash). |